|
|
|
|
|
CEOCFO CEOCFO Monthly Analyst |
We WILL win the
battle!
Technology Dendreon
Corporation
Martin A.
Simonetti Interview
conducted by: CEOCFOinterviews.com Bio of CFO Martin A. Simonetti has served as the Chief Financial Officer and Treasurer since joining the company in January 1999 and Senior Vice President, Finance since January 2001. From 1991 to 1998, Mr. Simonetti was employed at Amgen Inc., a pharmaceutical company, where he held various positions, including Vice-President Operations and Finance of Amgen BioPharma and their Director of Colorado Operations. From 1984 to 1991, he was employed at Genentech, Inc., a biotechnology company, first as a scientist in their Medicinal and Analytical Chemistry Department and later, after obtaining an M.B.A., as a financial analyst and quality group controller. Mr. Simonetti received a B.S. and M.S. in Nutrition from the University of California, Davis and an M.B.A. from the University of Santa Clara. About Dendreon Corporation Dendreon
Corporation, founded in 1992, discovers and develops immunologically based therapeutic
products for the treatment of cancer. The Company’s lead product, Provenge, is a
therapeutic vaccine for the treatment of prostate cancer and is in Phase III clinical
trials, the final stage of product development. Dendreon is conducting Phase II clinical
trials for Mylovenge, its therapeutic vaccine for the treatment of multiple myeloma. The
Company’s vaccine for the treatment of breast, ovarian and colon cancer, APC8024 is
in Phase I clinical trials. The Company has additional therapeutic vaccines in preclinical
development for the treatment of common malignancies, including lung, bladder and uterine
cancers. Together, these vaccines address the
eight most common cancers in the Western hemisphere. Mr.
Simonetti –
We have one product that is currently in 3 Phase III trials and that is Provenge. Two of these Phase III trials are for hormone
refractory prostate cancer. We announced
during men’s healthcare week, a Phase III trial in earlier stage prostate cancer for
that product as well. We also have
Mylovenge, which is in late Phase II studies for multiple myeloma, and we recently
announced the start of our third therapeutic vaccine cancer for our product APC8024 in
breast and ovarian cancers. Then we have 2
products in pre-clinical studies as well. These
vaccine candidates target multiple cancers, including lung, bladder, ovarian, breast and
prostate cancers. CEOCFOinterviews – Are you focusing strictly on cancer or do
you see yourself expanding to other areas?
|
